Director, SingHealth Intellectual Property Office, SingHealth
• Speaker, Commercialisation and Translation Symposium, 18 Sep 2021
Dr Lye Whye Kei is Director of the SingHealth Intellectual Property Office (SHIP). He was previously the Director of Business Development (Future Health Care) at the NTUitive Pte Ltd, the technology transfer arm of the Nanyang Technological University (NTU) in Singapore where he led the creation of several programmes to support the translational development of drugs/therapeutics and medical devices.
Prior to NTU, Dr Lye was CTO-founder of Setagon, Inc., a startup which developed several proprietary stent technologies, including a metallic nanoporous surface modification for medical devices such as coronary stents. Setagon obtained over US$5.5 million in venture financing and was acquired by Medtronic.
Dr Lye is the primary inventor of the acquired technology and has over 28 patents/patent applications. His technical experience includes work in the fields of nanoscale materials, micro-electromechanical systems, and biological nanosystems. He has a B.Sc. (Honors) from the California Institute of Technology, and a PhD from Yale University.